Vitrectomy outcomes are affected by retinoschisis in myopic macular holes

Article

Vitrectomy used to treat highly myopic macula holes (HMMHs) is negatively affected by retinoschisis.

Vitrectomy used to treat highly myopic macula holes (HMMHs) is negatively affected by retinoschisis, claims a study in the British Journal of Ophthalmology.

Dr Yasushi Ikuno et al., Department of Ophthalmology, Osaka University Medical School, Yamadaoka, Japan, performed a retrospective cross-sectional study on 22 eyes with HMMHs that underwent vitrectomy.

All eyes were split into two groups. Ten eyes were identified with retinoschisis and 12 did not have retinoschisis. Posterior staphyloma height was measured by optical coherence tomography (OCT). The surgical outcomes were postoperative final best-corrected visual acuity (BCVA) and reoperation rate.

Postoperative BCVA was strongly linked to presence or absence of retinoschisis and preoperative BCVA. The schisis group presented with a worse visual acuity and a greater posterior staphyloma height than the non-schisis group.

Highly myopic eyes presented with two types of macula holes with significantly different prognosis. The investigation suggests the careful interpretation of preoperative OCT images to identify accurate surgical results.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.